Agios Pharmaceuticals | AGIO - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 14.39B 1.85B 2026-06
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
Amgen USD 5.87B 1.02B 2026-03
Arrowhead Research USD 75.25M 1.52M 2026-06
Astellas Pharma JPY 482.54B 38.28B 2026-06
AstraZeneca USD 12.86B 251M 2026-06
Bayer EUR 6.33B 1.84B 2026-06
Biogen USD 2.12B 307M 2026-06
BioMarin Pharmaceutical USD 713.42M 142.21M 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Daiichi Sankyo JPY 287.15B 152.68B 2026-03
Eli Lilly USD 16.22B 301.7M 2026-03
Exelixis USD 608.03M 17.17M 2026-06
Gilead Sciences USD 6.8B 1.29B 2026-06
GlaxoSmithKline GBP 6.51B 757M 2026-06
Incyte USD 1.57B 400.89M 2026-06
Ionis Pharmaceuticals USD 265M 22M 2026-06
Merck USD 12.09B 1.24B 2026-03
Moderna USD -566M 792M 2026-03
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Novartis USD 11.24B 1.18B 2026-06
Novartis USD 10.07B 758M 2026-03
Pfizer USD -248M 11.29B 2026-06
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Roche Holding CHF 22.69B 600M 2026-06
Sarepta Therapeutics USD 251.15M 370.2M 2026-06
Vertex Pharmaceuticals USD 2.84B 242.4M 2026-06